Background: Mammary hamartoma is a benign rare tumour occurring in both sexes, with size range mostly between 2-4 cm. Giant breast hamartoma (GMH) is very rare and can reach unexpected sizes in women.

Presentation Of The Case: A 26 year old Egyptian female presented with left breast lump since 3 years, gradually increasing in size, with no other associated complaints. No family history of breast cancer, she did not smoke or consume alcohol, and had no past medical history. Examination revealed a large soft freely mobile mass (12 × 9 cm) in the lower outer quadrant of the left breast at the 3-6 o'clock position. There were no palpable axillary lymph nodes in both sides. Nipples and right breast were normal.

Discussion: The diagnosis of GMH can be made by examination and imaging only. The specific features that appear in mammogram and ultrasound can be used to reduce the need for core biopsy in hamartoma. Wide local excision is curative. We include a review of the literature of cases of GMH > 10 cm published during the last 15 years.

Conclusion: A non-invasive mammogram and ultrasound provide sufficient evidence of the tumour, hence core biopsy might not be critically required. However, if a breast hamartoma is still clinically suspected but with inconclusive or unequivocal mammographic and ultrasonographic features or if there is suspicion of dysplasia, then invasive core biopsy is justified. Recurrence is low and prognosis is good.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770458PMC
http://dx.doi.org/10.1016/j.ijscr.2020.11.139DOI Listing

Publication Analysis

Top Keywords

core biopsy
12
mammary hamartoma
8
review literature
8
breast hamartoma
8
left breast
8
mammogram ultrasound
8
breast
6
hamartoma
5
giant mammary
4
hamartoma middle
4

Similar Publications

Soft tissue and bone tumors are rare, and their low frequency and diverse histological types make conducting large-scale clinical trials challenging. Patient-derived xenografts (PDX), entailing implantation of cancer specimens in immunocompromised mice, are emerging as a valuable translational model because PDX keeps the original tumors' character and drug sensitivity. We sequentially transplanted 166 surgical and biopsy specimens from orthopedic surgeries, including 138 soft tissue and bone tumors (81 malignant, 23 intermediate, and 34 benign), 16 metastatic bone tumors, 9 hematological malignancies, and 3 non-tumor tissues.

View Article and Find Full Text PDF

Response of mucinous breast carcinoma to neoadjuvant chemotherapy.

Turk J Med Sci

December 2024

Department of Surgery, Division of General Surgery, Faculty of Medicine, İstanbul University, İstanbul, Turkiye.

Background/aim: Mucinous breast carcinoma (MBC) is thought to be a favorable-differentiated form of invasive breast cancer and is rarely preferred for neoadjuvant chemotherapy (NAC). The study aimed to define the response of MBCs to NAC.

Materials And Methods: A review was made of the demographic, clinicopathologic characteristics, management and follow-up data of 70 patients diagnosed with MBC between May 2010 and December 2020 by examining the patients' historical files and oncology records.

View Article and Find Full Text PDF

Objectives: To determine how many cores should be collected per region of interest in magnetic resonance imaging (MRI)-guided fusion prostate biopsy. MRI-guided targeted prostate biopsy has led to improved detection of clinically significant prostate cancer (csPC); however, data is limited regarding the optimal number of biopsy cores that should be taken. An ideal number of cores maximizes clinically significant cancer detection while minimizing cost, discomfort, and procedure time.

View Article and Find Full Text PDF

Trends in diagnostic biopsy sample collection approaches for primary bone sarcomas have shifted in the past 2 decades. Although open/incisional biopsies used to be the predominant approach to obtain diagnostic material for Ewing sarcoma and osteosarcoma, image-guided core needle biopsies have increased in frequency and are safe for patients. These procedures are less invasive and reduce recovery times but have potential limitations.

View Article and Find Full Text PDF

Purpose: The purpose of this study was to report the management of chemoimmunotherapy-resistant ocular surface squamous neoplasia (OSSN) with iodine-125 (I-125) brachytherapy.

Methods: A 36-year-old man presented to the clinic with biopsy-proven OSSN that covered ∼70% of the corneal surface and extended to the 6 o'clock position of the inferior limbus of the OS. The visual acuity was 20/20 in the OD and 20/40 in the affected OS.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!